Education
About Us
Working with TipRanks
Follow Us
ImmunityBio (IBRX)
NASDAQ:IBRX
Total Valuation
ImmunityBio has a market cap or net worth of $2.32B. The enterprise value is $2.52B.
Market Cap$2.32B
Enterprise Value$2.52B
Share Statistics
ImmunityBio has 882,466,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding882,466,900
Owned by Insiders74.13%
Owned by Institutions0.10%
Financial Efficiency
ImmunityBio’s return on equity (ROE) is 0.85 and return on invested capital (ROIC) is -100.37%.
Return on Equity (ROE)0.85
Return on Assets (ROA)-1.08
Return on Invested Capital (ROIC)-100.37%
Return on Capital Employed (ROCE)-1.05
Revenue Per Employee21.68K
Profits Per Employee-608.30K
Employee Count680
Asset Turnover0.04
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ImmunityBio is -4.32. ImmunityBio’s PEG ratio is 0.09.
PE Ratio-4.32
PS Ratio156.86
PB Ratio-3.66
Price to Fair Value-3.66
Price to FCF-4.48
Price to Operating Cash Flow-4.56
PEG Ratio0.09
Income Statement
In the last 12 months, ImmunityBio had revenue of 14.74M and earned -413.56M in profits. Earnings per share was -0.59.
Revenue14.74M
Gross Profit14.74M
Operating Income-344.18M
Pretax Income-413.56M
Net Income-413.56M
EBITDA-264.43M
Earnings Per Share (EPS)-0.59
Cash Flow
In the last 12 months, operating cash flow was -391.24M and capital expenditures -4.78M, giving a free cash flow of -396.01M billion.
Operating Cash Flow-391.24M
Free Cash Flow-396.01M
Free Cash Flow per Share-0.45
Dividends & Yields
ImmunityBio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.59
52-Week Price Change-70.97%
50-Day Moving Average2.92
200-Day Moving Average3.77
Relative Strength Index (RSI)45.65
Average Volume (3m)6.55M
Important Dates
ImmunityBio upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateMar 3, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
ImmunityBio as a current ratio of 3.36, with Debt / Equity ratio of -103.29%
Current Ratio3.36
Quick Ratio3.21
Debt to Market Cap0.02
Net Debt to EBITDA0.38
Interest Coverage Ratio-2.61
Taxes
In the past 12 months, ImmunityBio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
ImmunityBio EV to EBITDA ratio is -6.37, with an EV/FCF ratio of -4.23.
EV to Sales114.21
EV to EBITDA-6.37
EV to Free Cash Flow-4.23
EV to Operating Cash Flow-4.30
Balance Sheet
ImmunityBio has $149.81M in cash and marketable securities with $2.47M in debt, giving a net cash position of $354.36M billion.
Cash & Marketable Securities$149.81M
Total Debt$2.47M
Net Cash$354.36M
Net Cash Per Share$0.40
Tangible Book Value Per Share-$0.72
Margins
Gross margin is 69.11%, with operating margin of -2334.23%, and net profit margin of -2804.77%.
Gross Margin69.11%
Operating Margin-2334.23%
Pretax Margin-2804.77%
Net Profit Margin-2804.77%
EBITDA Margin-1793.37%
EBIT Margin-1912.42%
Analyst Forecast
The average price target for ImmunityBio is $6.08, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.08
Price Target Upside132.95% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast2270.58%
EPS Growth Forecast46.82%